Emerging drugs for the treatment of anxiety

Expert Opinion on Emerging Drugs

Volumn 20, Issue 3, 2015, Pages 393-406

  Murrough, James W ^a   Yaqubi, Sahab ^b   Sayed, Sehrish ^a   Charney, Dennis S ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b ELMHURST HOSPITAL CENTER   (United States)

Author keywords

anxiety; anxiolytic; clinical trial; endocannabinoid; glutamate; neuropeptide; panic disorder; posttraumatic stress disorder

Indexed keywords

4 AMINOBUTYRIC ACID; AGOMELATINE; ANXIOLYTIC AGENT; ARIPIPRAZOLE; BREXPIPRAZOLE; CHOLECYSTOKININ; CORTICOTROPIN RELEASING FACTOR; CYCLOSERINE; DOPAMINE; ENDOCANNABINOID; GLUTAMIC ACID; GUANFACINE; KETAMINE; MELATONIN; METABOTROPIC RECEPTOR; NEUROLEPTIC AGENT; NEUROPEPTIDE; NEUROPEPTIDE Y; NORADRENALIN; PREGABALIN; SEROTONIN; SUBSTANCE P; VILAZODONE; VORTIOXETINE;

ANXIETY; ANXIETY DISORDER; ARTICLE; ENVIRONMENT; GENERALIZED ANXIETY DISORDER; HUMAN; MEDICAL RESEARCH; NONHUMAN; PANIC; POSTTRAUMATIC STRESS DISORDER; PSYCHOTHERAPY; SOCIAL PHOBIA; ANIMAL; ANXIETY DISORDERS; DISEASE MODEL; DRUG DESIGN; MOLECULARLY TARGETED THERAPY; PATHOPHYSIOLOGY;

ANIMALS; ANTI-ANXIETY AGENTS; ANXIETY; ANXIETY DISORDERS; DISEASE MODELS, ANIMAL; DRUG DESIGN; HUMANS; MOLECULAR TARGETED THERAPY;

EID: 84940396684     PISSN: 14728214     EISSN: 17447623     Source Type: Journal    
DOI: 10.1517/14728214.2015.1049996     Document Type: Article

References (132)

1. Kessler RC, Chiu WT, Demler O. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the national comorbidity survey replication. Arch Gen Psychiatry 2005 62(6): 617-27
2. Erickson SR, Guthrie S, Vanetten-Lee M, et al. Severity of anxiety and work-related outcomes of patients with anxiety disorders. Depress Anxiety. 2009; 26(12): 1165-71
3. Schaffer A, McIntosh D, Goldstein BI, et al. The CANMAT task force recommendations for the management of patients with mood disorders and comorbid anxiety disorders. Ann Clin Psychiatry. 2012 24(1): 6-22
4. Nepon J, Belik SL, Bolton J, Sareen J. The relationship between anxiety disorders and suicide attempts: Findings from the national epidemiologic survey on alcohol and related conditions. Depress Anxiety. 2010 27(9): 791-8
5. Diagnostic and statistical manual of mental disorders. 5th edition (DSM-5). American Psychiatric Association, Washington, DC; 2013
6. Morrison FG, Ressler KJ. From the neurobiology of extinction to improved clinical treatments. Depress Anxiety. 2014 31(4): 279-90.
7. Griebel G, Holmes A. 50 years of hurdles and hope in anxiolytic drug discovery. Nat Rev Drug Discov. 2013 12(9): 667-87.
8. Senaratne R, Van Ameringen M, Mancini C, Patterson B. The burden of anxiety disorders on the family. J Nerv Ment Dis. 2010 198(12): 876-80
9. Martin-Merino E, Ruigomez A, Wallander MA, et al. Prevalence, incidence, morbidity and treatment patterns in a cohort of patients diagnosed with anxiety in UK primary care. Fam Pract. 2010 27(1): 9-16
10. Waghorn G, Chant D, White P, Whiteford H. Disability, employment and work performance among people with ICD-10 anxiety disorders. Aust N Z J Psychiatry. 2005 39(1-2): 55-66
11. Watanabe N, Churchill R, Furukawa TA. Combined psychotherapy plus benzodiazepines for panic disorder. Cochrane Database Syst Rev. 2009; (1): CD005335
12. Imai H, Tajika A, Chen P, et al. Azapirones versus placebo for panic disorder in adults. Cochrane Database Syst Rev. 2014 9: CD010828
13. Stein DJ, Ipser JC, Seedat S. Pharmacotherapy for post traumatic stress disorder (PTSD). Cochrane Database Syst Rev. 2006; (1): CD002795.
14. Kapczinski F, Lima MS, Souza JS, Schmitt R. Antidepressants for generalized anxiety disorder. Cochrane Database Syst Rev. 2003; (2): CD003592
15. Treatment of posttraumatic stress disorder: An assessment of the evidence. National Academies Press. Institute of Medicine, Washington, D. C; 2008
16. Stein MB, Stein DJ. Social anxiety disorder. Lancet. 2008 371(9618): 1115-25
17. Baldwin DS, Waldman S, Allgulander C. Evidence-based pharmacological treatment of generalized anxiety disorder. Int J Neuropsychopharmacol. 2011 14(5): 697-710
18. Cuijpers P, Sijbrandij M, Koole SL, et al. The efficacy of psychotherapy and pharmacotherapy in treating depressive and anxiety disorders: A meta-analysis of direct comparisons. World Psychiatry. 2013 12(2): 137-48
19. Otto MW, Tuby KS, Gould RA, et al. An effect-size analysis of the relative efficacy and tolerability of serotonin selective reuptake inhibitors for panic disorder. Am J Psychiatry. 2001 158(12): 1989-92
20. Goddard AW, Brouette T, Almai A, et al. Early coadministration of clonazepam with sertraline for panic disorder. Arch Gen Psychiatry. 2001 58(7): 681-6
21. Cuthbert BN. The RDoC framework: facilitating transition from ICD/DSM to dimensional approaches that integrate neuroscience and psychopathology. World Psychiatry. 2014 13(1): 28-35.
22. Armour C, Carragher N, Elhai JD. Assessing the fit of the dysphoric arousal model across two nationally representative epidemiological surveys: The australian NSMHWB and the united states NESARC. J Anxiety Disord. 2013 27(1): 109-15
23. Pietrzak RH, Averill LA, Abdallah CG, et al. Amygdala-hippocampal volume and the phenotypic heterogeneity of posttraumatic stress disorder: A crosssectional study. JAMA Psychiatry. 2015; 72(4): 396-8
24. Bang-Andersen B, Ruhland T, Jorgensen M, et al. Discovery of 1-[2-(2, 4-dimethylphenylsulfanyl)phenyl] piperazine (lu AA21004): A novel multimodal compound for the treatment of major depressive disorder. J Med Chem. 2011 54(9): 3206-21
25. Gibb A, Deeks ED. Vortioxetine: First global approval. Drugs. 2014 74(1): 135-45
26. Bidzan L, Mahableshwarkar AR, Jacobsen P, et al. Vortioxetine (lu AA21004) in generalized anxiety disorder: Results of an 8-week, multinational, randomized, double-blind, placebo-controlled clinical trial. Eur Neuropsychopharmacol. 2012 22(12): 847-57
27. Rothschild AJ, Mahableshwarkar AR, Jacobsen P, et al. Vortioxetine (lu AA21004) 5 mg in generalized anxiety disorder: Results of an 8-week randomized, double-blind, placebocontrolled clinical trial in the united states. Eur Neuropsychopharmacol. 2012 22(12): 858-66
28. Mahableshwarkar AR, Jacobsen PL, Serenko M, Chen Y. A randomized, double-blind, fixed-dose study comparing the efficacy and tolerability of vortioxetine 2. 5 and 10 mg in acute treatment of adults with generalized anxiety disorder. Hum Psychopharmacol. 2014 29(1): 64-72
29. Baldwin DS, Loft H, Florea I. Lu AA21004, a multimodal psychotropic agent, in the prevention of relapse in adult patients with generalized anxiety disorder. Int Clin Psychopharmacol. 2012 27(4): 197-207
30. Dawson LA. The discovery and development of vilazodone for the treatment of depression: A novel antidepressant or simply another SSRI? Expert Opin Drug Discov. 2013 8(12): 1529-39
31. Pierz KA, Thase ME. A review of vilazodone, serotonin, and major depressive disorder. Prim Care Companion CNS Disord. 2014; 16(1): 10. 4088/PCC. 13r01554
32. Thase ME, Chen D, Edwards J, Ruth A. Efficacy of vilazodone on anxiety symptoms in patients with major depressive disorder. Int Clin Psychopharmacol. 2014 29(6): 351-6
33. Clayton AH, Pradko JF, Croft HA, et al. Prevalence of sexual dysfunction among newer antidepressants. J Clin Psychiatry. 2002 63(4): 357-66
34. Tardito D, Molteni R, Popoli M, Racagni G. Synergistic mechanisms involved in the antidepressant effects of agomelatine. Eur Neuropsychopharmacol. 2012; 22(Suppl 3): S482-6
35. Soumier A, Banasr M, Lortet S, et al. Mechanisms contributing to the phasedependent regulation of neurogenesis by the novel antidepressant, agomelatine, in the adult rat hippocampus. Neuropsychopharmacology. 2009 34(11): 2390-403
36. Stein DJ, Ahokas AA, de Bodinat C. Efficacy of agomelatine in generalized anxiety disorder: A randomized, doubleblind, placebo-controlled study. J Clin Psychopharmacol. 2008 28(5): 561-6
37. Stein DJ, Ahokas A, Marquez MS, et al. Agomelatine in generalized anxiety disorder: An active comparator and placebo-controlled study. J Clin Psychiatry. 2014 75(4): 362-8
38. Stein DJ, Ahokas A, Albarran C, et al. Agomelatine prevents relapse in generalized anxiety disorder: A 6-month randomized, double-blind, placebocontrolled discontinuation study. J Clin Psychiatry. 2012 73(7): 1002-8
39. Stein DJ, Picarel-Blanchot F, Kennedy SH. Efficacy of the novel antidepressant agomelatine for anxiety symptoms in major depression. Hum Psychopharmacol. 2013 28(2): 151-9
40. De Berardis D, Conti CM, Marini S, et al. Is there a role for agomelatine in the treatment of anxiety disorders? A review of published data. Int J Immunopathol Pharmacol. 2013 26(2): 299-304
41. Bremner JD, Krystal JH, Southwick SM, Charney DS. Noradrenergic mechanisms in stress and anxiety: I. preclinical studies. Synapse. 1996 23(1): 28-38
42. Bremner JD, Krystal JH, Southwick SM, Charney DS. Noradrenergic mechanisms in stress and anxiety: II. clinical studies. Synapse. 1996 23(1): 39-51
43. Pfau ML, Russo SJ. Peripheral and central mechanisms of stress resilience. Neurobiol Stress. 2015 1: 66-79
44. Arnsten AF, Raskind MA, Taylor FB, Connor DF. The effects of stress exposure on prefrontal cortex: Translating basic research into successful treatments for post-traumatic stress disorder. Neurobiol Stress. 2015 1: 89-99
45. Geracioti TD Jr, Baker DG, Ekhator NN, et al. CSF norepinephrine concentrations in posttraumatic stress disorder. Am J Psychiatry. 2001 158(8): 1227-30
46. Strawn JR, Geracioti TD Jr. Noradrenergic dysfunction and the psychopharmacology of posttraumatic stress disorder. Depress Anxiety. 2008; 25(3): 260-71
47. Connor DF, Arnsten AF, Pearson GS, Greco GF. Guanfacine extended release for the treatment of attention-deficit/ hyperactivity disorder in children and adolescents. Expert Opin Pharmacother. 2014 15(11): 1601-10
48. Neylan TC, Lenoci M, Samuelson KW, et al. No improvement of posttraumatic stress disorder symptoms with guanfacine treatment. Am J Psychiatry. 2006 163(12): 2186-8
49. Davis LL, Ward C, Rasmusson A, et al. A placebo-controlled trial of guanfacine for the treatment of posttraumatic stress disorder in veterans. Psychopharmacol Bull. 2008; 41(1): 8-18
50. Connor DF, Grasso DJ, Slivinsky MD, et al. An open-label study of guanfacine extended release for traumatic stress related symptoms in children and adolescents. J Child Adolesc Psychopharmacol. 2013 23(4): 244-51
51. Colombo G, Maccioni P, Vargiolu D, et al. The dopamine beta-hydroxylase inhibitor, nepicastat, reduces different alcohol-related behaviors in rats. Alcohol Clin Exp Res. 2014 38(9): 2345-53
52. Sayyah M, Sayyah M, Boostani H, et al. Effects of aripiprazole augmentation in treatment-resistant obsessive-compulsive disorder (a double blind clinical trial). Depress Anxiety. 2012 29(10): 850-4
53. Muscatello MR, Bruno A, Pandolfo G, et al. Effect of aripiprazole augmentation of serotonin reuptake inhibitors or clomipramine in treatment-resistant obsessive-compulsive disorder: A doubleblind, placebo-controlled study. J Clin Psychopharmacol. 2011 31(2): 174-9
54. Hoge EA, Worthington JJ III, Kaufman RE, et al. Aripiprazole as augmentation treatment of refractory generalized anxiety disorder and panic disorder. CNS Spectr. 2008 13(6): 522-7
55. Adson DE, Kushner MG, Fahnhorst TA. Treatment of residual anxiety symptoms with adjunctive aripiprazole in depressed patients taking selective serotonin reuptake inhibitors. J Affect Disord. 2005 86(1): 99-104
56. Mello MF, Costa MC, Schoedl AF, Fiks JP. Aripiprazole in the treatment of posttraumatic stress disorder: An openlabel trial. Rev Bras Psiquiatr. 2008 30(4): 358-61
57. Khan A, Joyce M, Atkinson S, et al. A randomized, double-blind study of once-daily extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with generalized anxiety disorder. J Clin Psychopharmacol. 2011 31(4): 418-28
58. Merideth C, Cutler AJ, She F, Eriksson H. Efficacy and tolerability of extended release quetiapine fumarate monotherapy in the acute treatment of generalized anxiety disorder: A randomized, placebo controlled and active-controlled study. Int Clin Psychopharmacol. 2012 27(1): 40-54
59. Brawman-Mintzer O, Knapp RG, Nietert PJ. Adjunctive risperidone in generalized anxiety disorder: A doubleblind, placebo-controlled study. J Clin Psychiatry. 2005 66(10): 1321-5
60. Pandina GJ, Canuso CM, Turkoz I, et al. Adjunctive risperidone in the treatment of generalized anxiety disorder: A double-blind, prospective, placebocontrolled, randomized trial. Psychopharmacol Bull. 2007; 40(3): 41-57
61. Krystal JH, Rosenheck RA, Cramer JA, et al. Adjunctive risperidone treatment for antidepressant-resistant symptoms of chronic military service-related PTSD: A randomized trial. JAMA. 2011 306(5): 493-502
62. Tassone DM, Boyce E, Guyer J, Nuzum D. Pregabalin: A novel gammaaminobutyric acid analogue in the treatment of neuropathic pain, partialonset seizures, and anxiety disorders. Clin Ther. 2007 29(1): 26-48
63. Rickels K, Pollack MH, Feltner DE, et al. Pregabalin for treatment of generalized anxiety disorder: A 4-week, multicenter, double-blind, placebocontrolled trial of pregabalin and alprazolam. Arch Gen Psychiatry. 2005 62(9): 1022-30
64. Kasper S, Herman B, Nivoli G, et al. Efficacy of pregabalin and venlafaxine-XR in generalized anxiety disorder: Results of a double-blind, placebocontrolled 8-week trial. Int Clin Psychopharmacol. 2009 24(2): 87-96
65. Baldwin D, Woods R, Lawson R, Taylor D. Efficacy of drug treatments for generalised anxiety disorder: Systematic review and meta-analysis. BMJ. 2011 342: d1199
66. Pande AC, Crockatt JG, Feltner DE, et al. Pregabalin in generalized anxiety disorder: A placebo-controlled trial. Am J Psychiatry. 2003 160(3): 533-40
67. Oulis P, Mourikis I, Konstantakopoulos G. Pregabalin augmentation in treatment-resistant obsessive-compulsive disorder. Int Clin Psychopharmacol. 2011 26(4): 221-4
68. Baniasadi M, Hosseini G, Fayyazi Bordbar MR, et al. Effect of pregabalin augmentation in treatment of patients with combat-related chronic posttraumatic stress disorder: A randomized controlled trial. J Psychiatr Pract. 2014 20(6): 419-27
69. Mula M. Treatment of anxiety disorders in epilepsy: An evidence-based approach. Epilepsia. 2013 54(Suppl 1): 13-18
70. Lapidus KA, Soleimani L, Murrough JW. Novel glutamatergic drugs for the treatment of mood disorders. Neuropsychiatr Dis Treat. 2013; 9: 1101-12
71. Zarate CA Jr, Singh JB, Carlson PJ, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatmentresistant major depression. Arch Gen Psychiatry. 2006 63(8): 856-64
72. Murrough JW, Iosifescu DV, Chang LC, et al. Antidepressant efficacy of ketamine in treatment-resistant major depression: A two-site randomized controlled trial. Am J Psychiatry. 2013 170(10): 1134-42
73. Wan LB, Levitch CF, Perez AM, et al. Ketamine safety and tolerability in clinical trials for treatment-resistant depression. J Clin Psychiatry. 2015; 76(3): 247-52
74. McGirr A, Berlim MT, Bond DJ, et al. A systematic review and meta-analysis of randomized, double-blind, placebocontrolled trials of ketamine in the rapid treatment of major depressive episodes. Psychol Med. 2015 45(4): 693-704
75. Feder A, Parides MK, Murrough JW, et al. Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: A randomized clinical trial. JAMA Psychiatry. 2014 71(6): 681-8
76. Bloch MH, Wasylink S, Landeros-Weisenberger A, et al. Effects of ketamine in treatment-refractory obsessive-compulsive disorder. Biol Psychiatry. 2012 72(11): 964-70
77. Rodriguez CI, Kegeles LS, Levinson A, et al. Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder: Proof-of-concept. Neuropsychopharmacology. 2013 38(12): 2475-83
78. Krystal JH, Mathew SJ, D'Souza DC, et al. Potential psychiatric applications of metabotropic glutamate receptor agonists and antagonists. CNS Drugs. 2010 24(8): 669-93
79. Wieronska JM, Pilc A. Glutamate-based anxiolytic ligands in clinical trials. Expert Opin Investig Drugs. 2013 22(8): 1007-22
80. Dunayevich E, Erickson J, Levine L, et al. Efficacy and tolerability of an mGlu2/3 agonist in the treatment of generalized anxiety disorder. Neuropsychopharmacology. 2008 33(7): 1603-10
81. Bergink V, Westenberg HG. Metabotropic glutamate II receptor agonists in panic disorder: A double blind clinical trial with LY354740. Int Clin Psychopharmacol. 2005 20(6): 291-3
82. Singewald N, Schmuckermair C, Whittle N, et al. Pharmacology of cognitive enhancers for exposure-based therapy of fear, anxiety and traumarelated disorders. Pharmacol Ther. 2015 149: 150-90
83. Bukalo O, Pinard CR, Holmes A. Mechanisms to medicines: elucidating neural and molecular substrates of fear extinction to identify novel treatments for anxiety disorders. Br J Pharmacol. 2014 171(20): 4690-718
84. Difede J, Cukor J, Wyka K, et al. D-cycloserine augmentation of exposure therapy for post-traumatic stress disorder: A pilot randomized clinical trial. Neuropsychopharmacology. 2014 39(5): 1052-8
85. Ressler KJ, Rothbaum BO, Tannenbaum L, et al. Cognitive enhancers as adjuncts to psychotherapy: use of D-cycloserine in phobic individuals to facilitate extinction of fear. Arch Gen Psychiatry. 2004 61(11): 1136-44
86. Otto MW, Tolin DF, Simon NM, et al. Efficacy of d-cycloserine for enhancing response to cognitive-behavior therapy for panic disorder. Biol Psychiatry. 2010 67(4): 365-70
87. Chalmers DT, Lovenberg TW, De Souza EB. Localization of novel corticotropin-releasing factor receptor (CRF2) mRNA expression to specific subcortical nuclei in rat brain: Comparison with CRF1 receptor mRNA expression. J Neurosci. 1995 15(10): 6340-50
88. Bale TL, Vale WW. CRF and CRF receptors: role in stress responsivity and other behaviors. Annu Rev Pharmacol Toxicol. 2004; 44: 525-57
89. Holsboer F. The rationale for corticotropin-releasing hormone receptor (CRH-R) antagonists to treat depression and anxiety. J Psychiatr Res. 1999 33(3): 181-214
90. Baldwin HA, Rassnick S, Rivier J, et al. CRF antagonist reverses the "anxiogenic" response to ethanol withdrawal in the rat. Psychopharmacology (Berl). 1991; 103(2): 227-32
91. Dunn AJ, File SE. Corticotropin-releasing factor has an anxiogenic action in the social interaction test. Horm Behav. 1987 21(2): 193-202
92. Gehlert DR, Shekhar A, Morin SM, et al. Stress and central urocortin increase anxiety-like behavior in the social interaction test via the CRF1 receptor. Eur J Pharmacol. 2005 509(2-3): 145-53
93. Baker DG, West SA, Nicholson WE, et al. Serial CSF corticotropin-releasing hormone levels and adrenocortical activity in combat veterans with posttraumatic stress disorder. Am J Psychiatry. 1999 156(4): 585-8
94. Sautter FJ, Bissette G, Wiley J, et al. Corticotropin-releasing factor in posttraumatic stress disorder (PTSD) with secondary psychotic symptoms, nonpsychotic PTSD, and healthy control subjects. Biol Psychiatry. 2003 54(12): 1382-8
95. Holsboer F, Ising M. Central CRH system in depression and anxiety-evidence from clinical studies with CRH1 receptor antagonists. Eur J Pharmacol. 2008 583(2-3): 350-7
96. Coric V, Feldman HH, Oren DA, et al. Multicenter, randomized, double-blind, active comparator and placebo-controlled trial of a corticotropin-releasing factor receptor-1 antagonist in generalized anxiety disorder. Depress Anxiety. 2010 27(5): 417-25
97. Tellew JE, Lanier M, Moorjani M, et al. Discovery of NBI-77860/GSK561679, a potent corticotropin-releasing factor (CRF1) receptor antagonist with improved pharmacokinetic properties. Bioorg Med Chem Lett. 2010 20(24): 7259-64
98. Dunlop BW, Rothbaum BO, Binder EB, et al. Evaluation of a corticotropin releasing hormone type 1 receptor antagonist in women with posttraumatic stress disorder: Study protocol for a randomized controlled trial. Trials. 2014; 15: 240
99. Brothers SP, Wahlestedt C. Therapeutic potential of neuropeptide Y (NPY) receptor ligands. EMBO Mol Med. 2010 2(11): 429-39
100. Wu G, Feder A, Wegener G, et al. Central functions of neuropeptide Y in mood and anxiety disorders. Expert Opin Ther Targets. 2011 15(11): 1317-31
101. Griebel G, Holsboer F. Neuropeptide receptor ligands as drugs for psychiatric diseases: The end of the beginning? Nat Rev Drug Discov. 2012 11(6): 462-78
102. Longo A, Mele P, Bertocchi I, et al. Conditional inactivation of neuropeptide Y Y1 receptors unravels the role of Y1 and Y5 receptors coexpressing neurons in anxiety. Biol Psychiatry. 2014 76(11): 840-9
103. Roseboom PH, Nanda SA, Fox AS, et al. Neuropeptide Y receptor gene expression in the primate amygdala predicts anxious temperament and brain metabolism. Biol Psychiatry. 2014 76(11): 850-7
104. Heilig M. The NPY system in stress, anxiety and depression. Neuropeptides. 2004 38(4): 213-24
105. Serova LI, Tillinger A, Alaluf LG, et al. Single intranasal neuropeptide Y infusion attenuates development of PTSD-like symptoms to traumatic stress in rats. Neuroscience. 2013 236: 298-312
106. Rasmusson AM, Hauger RL, Morgan CA, et al. Low baseline and yohimbine-stimulated plasma neuropeptide Y (NPY) levels in combatrelated PTSD. Biol Psychiatry. 2000 47(6): 526-39
107. Yehuda R, Brand S, Yang RK. Plasma neuropeptide Y concentrations in combat exposed veterans: Relationship to trauma exposure, recovery from PTSD, and coping. Biol Psychiatry. 2006 59(7): 660-3
108. Sah R, Ekhator NN, Strawn JR, et al. Low cerebrospinal fluid neuropeptide Y concentrations in posttraumatic stress disorder. Biol Psychiatry. 2009 66(7): 705-7
109. Sah R, Ekhator NN, Jefferson-Wilson L, et al. Cerebrospinal fluid neuropeptide Y in combat veterans with and without posttraumatic stress disorder. Psychoneuroendocrinology. 2014 40: 277-83
110. Kramer MS, Cutler N, Feighner J, et al. Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science. 1998 281(5383): 1640-5
111. Gobert A, Brocco M, Dekeyne A, et al. Neurokinin1 antagonists potentiate antidepressant properties of serotonin reuptake inhibitors, yet blunt their anxiogenic actions: A neurochemical, electrophysiological, and behavioral characterization. Neuropsychopharmacology. 2009 34(4): 1039-56
112. Hietala J, Nyman MJ, Eskola O, et al. Visualization and quantification of neurokinin-1 (NK1) receptors in the human brain. Mol Imaging Biol. 2005 7(4): 262-72
113. Herpfer I, Lieb K. Substance P receptor antagonists in psychiatry: Rationale for development and therapeutic potential. CNS Drugs. 2005; 19(4): 275-93
114. Ebner K, Singewald N. The role of substance P in stress and anxiety responses. Amino Acids. 2006 31(3): 251-72
115. Geracioti TD Jr, Carpenter LL, Owens MJ, et al. Elevated cerebrospinal fluid substance p concentrations in posttraumatic stress disorder and major depression. Am J Psychiatry. 2006 163(4): 637-43
116. Mathew SJ, Vythilingam M, Murrough JW, et al. A selective neurokinin-1 receptor antagonist in chronic PTSD: A randomized, doubleblind, placebo-controlled, proof-of-concept trial. Eur Neuropsychopharmacol. 2011 21(3): 221-9
117. Tauscher J, Kielbasa W, Iyengar S, et al. Development of the 2nd generation neurokinin-1 receptor antagonist LY686017 for social anxiety disorder. Eur Neuropsychopharmacol. 2010 20(2): 80-7
118. Wang H, Wong PT, Spiess J, Zhu YZ. Cholecystokinin-2 (CCK2) receptormediated anxiety-like behaviors in rats. Neurosci Biobehav Rev. 2005; 29(8): 1361-73
119. de Montigny C. Cholecystokinin tetrapeptide induces panic-like attacks in healthy volunteers. preliminary findings. Arch Gen Psychiatry. 1989 46(6): 511-17
120. Chhatwal JP, Gutman AR, Maguschak KA, et al. Functional interactions between endocannabinoid and CCK neurotransmitter systems may be critical for extinction learning. Neuropsychopharmacology. 2009 34(2): 509-21
121. Crowe MS, Nass SR, Gabella KM, Kinsey SG. The endocannabinoid system modulates stress, emotionality, and inflammation. Brain Behav Immun. 2014 42: 1-5
122. Howlett AC, Bidaut-Russell M, Devane WA, et al. The cannabinoid receptor: biochemical, anatomical and behavioral characterization. Trends Neurosci. 1990 13(10): 420-3
123. Marco EM, Garcia-Gutierrez MS, Bermudez-Silva FJ, et al. Endocannabinoid system and psychiatry: in search of a neurobiological basis for detrimental and potential therapeutic effects. Front Behav Neurosci. 2011 5: 63
124. Neumeister A, Normandin MD, Pietrzak RH, et al. Elevated brain cannabinoid CB1 receptor availability in post-traumatic stress disorder: A positron emission tomography study. Mol Psychiatry. 2013 18(9): 1034-40
125. Roitman P, Mechoulam R, Cooper-Kazaz R, Shalev A. Preliminary, open-label, pilot study of add-on oral Delta9-tetrahydrocannabinol in chronic post-traumatic stress disorder. Clin Drug Investig. 2014 34(8): 587-91
126. Bergamaschi MM, Queiroz RH, Chagas MH, et al. Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naive social phobia patients. Neuropsychopharmacology. 2011 36(6): 1219-26
127. Crippa JA, Zuardi AW, Martin-Santos R, et al. Cannabis and anxiety: A critical review of the evidence. Hum Psychopharmacol. 2009 24(7): 515-23
128. Moreira FA, Crippa JA. The psychiatric side-effects of rimonabant. Rev Bras Psiquiatr. 2009 31(2): 145-53
129. Micale V, Di Marzo V, Sulcova A, et al. Endocannabinoid system and mood disorders: Priming a target for new therapies. Pharmacol Ther. 2013 138(1): 18-37
130. Dincheva I, Drysdale AT, Hartley CA, et al. FAAH genetic variation enhances fronto-amygdala function in mouse and human. Nat Commun. 2015 6: 6395
131. Pitman RK, Rasmusson AM, Koenen KC, et al. Biological studies of post-traumatic stress disorder. Nat Rev Neurosci. 2012 13(11): 769-87
132. Mahan AL, Ressler KJ. Fear conditioning, synaptic plasticity and the amygdala: Implications for posttraumatic stress disorder. Trends Neurosci. 2012 35(1): 24-35.